Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Modified-Release Drug Delivery Systems: Influencing Factors01:20

Modified-Release Drug Delivery Systems: Influencing Factors

Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Future of Psoriasis Care.

Cutis·2026
Same author

Letter From the New Editor-in-Chief.

Journal of psoriasis and psoriatic arthritis·2026
Same author

Brodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence.

Journal of drugs in dermatology : JDD·2026
Same author

Topical roflumilast 0.3% cream for mild hidradenitis suppurativa: A prospective case series.

JAAD case reports·2026
Same author

Ethical implications of ensuring follow-up care for free skin cancer screenings.

Journal of the American Academy of Dermatology·2025
Same author

More Than Skin Clearance: Connecting Brodalumab's Mechanism of Action to Patient Outcomes in Psoriasis.

Journal of drugs in dermatology : JDD·2025

Related Experiment Video

Updated: Jun 13, 2026

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects
05:46

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects

Published on: May 4, 2021

Sustained release nitric oxide from long-lived circulating nanoparticles.

Pedro Cabrales1, George Han, Camille Roche

  • 1Department of Bioengineering, University of California, San Diego, La Jolla, CA 92093, USA. pcabrales@ucsd.edu

Free Radical Biology & Medicine
|May 13, 2010
PubMed
Summary
This summary is machine-generated.

New nitric oxide nanoparticles (NO-np) offer controlled, sustained NO release for cardiovascular disease treatment. These NO-np hydrate to release therapeutic NO, reducing blood pressure and inflammation.

More Related Videos

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries
08:58

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

Published on: February 25, 2016

Designing Porous Silicon Films as Carriers of Nerve Growth Factor
10:12

Designing Porous Silicon Films as Carriers of Nerve Growth Factor

Published on: January 25, 2019

Related Experiment Videos

Last Updated: Jun 13, 2026

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects
05:46

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects

Published on: May 4, 2021

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries
08:58

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

Published on: February 25, 2016

Designing Porous Silicon Films as Carriers of Nerve Growth Factor
10:12

Designing Porous Silicon Films as Carriers of Nerve Growth Factor

Published on: January 25, 2019

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Cardiovascular Research

Background:

  • Limitations in current nitric oxide (NO) delivery systems necessitate novel approaches.
  • Controlled and sustained NO generation is crucial for treating cardiovascular diseases.
  • Hydrogel/glass hybrid nanoparticles offer a new platform for NO delivery.

Purpose of the Study:

  • To develop and evaluate NO-releasing nanoparticles (NO-np) for controlled NO delivery.
  • To assess the physiological response to circulating NO-np infusion.
  • To investigate the therapeutic potential of NO-np in cardiovascular conditions.

Main Methods:

  • Preparation of NO-releasing nanoparticles (NO-np) using a hydrogel/glass hybrid platform.
  • Controlled release of NO triggered by nanoparticle hydration.
  • In vivo administration of NO-np and control nanoparticles (control-np) in a dose-dependent manner.
  • Monitoring of physiological parameters including mean arterial blood pressure, exhaled NO, microvascular perfusion, and inflammatory markers.

Main Results:

  • NO-np demonstrated sustained NO release regulated by hydration.
  • Circulating NO-np dose-dependently decreased mean arterial blood pressure and increased exhaled NO.
  • NO-np induced vasodilatation and improved microvascular perfusion.
  • Control-np induced adverse effects, including increased leukocyte rolling and immobilization, which were prevented by NO release from NO-np.

Conclusions:

  • NO-np provide a novel, hydration-dependent method for controlled and sustained NO release.
  • NO-np exhibit significant therapeutic potential for cardiovascular diseases by reducing blood pressure and preventing inflammation.
  • The NO-np platform offers advantages over other NO-releasing compounds due to its predictable release mechanism.